Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International expert panel meeting of the Italian association of thoracic oncology

Clinical Lung Cancer

Volumn 15, Issue 3, 2014, Pages 173-181

  Gridelli, Cesare ^a   De Marinis, Filippo ^b   Cappuzzo, Federico ^c   Di Maio, Massimo ^d   Hirsch, Fred R ^e   Mok, Tony ^f   Morgillo, Floriana ^g   Rosell, Rafael ^h   Spigel, David R ⁱ   Yang, James Chih Hsin ^j   Ciardiello, Fortunato ^g  

^a S G MOSCATI HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Livorno Hospital   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

ALK rearrangement; Epidermal growth factor receptor mutation; Non small cell lung cancer

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ALK GENE; BIOPSY TECHNIQUE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPARATIVE STUDY; EGFR GENE; GENE; GENE MUTATION; GENE REARRANGEMENT; LOCAL THERAPY; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; PROGRESSION FREE SURVIVAL; RESEARCH PRIORITY; REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE COURSE; GENETICS; HUMAN; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84898001764     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.12.002     Document Type: Review

References (55)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group BMJ 311 1995 899 909
2. M. Di Maio, A. Morabito, and M.C. Piccirillo et al. New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development Expert Opin Investig Drugs 19 2010 1503 1514
3. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
4. W. Pao, V. Miller, and M. Zakowski et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
5. T. Mitsudomi, S. Morita, and Y. Yatabe West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
6. M. Maemondo, A. Inoue, and K. Kobayashi North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
7. C. Zhou, Y.L. Wu, and G. Chen et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
8. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
9. L.V. Sequist, J.C. Yang, and N. Yamamoto et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3327 3334
10. Y.L. Wu, C. Zhou, and C.P. Hu et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 2014 213 222
11. T. Mitsudomi, T. Kosaka, and Y. Yatabe Biological and clinical implications of EGFR mutations in lung cancer Int J Clin Oncol 11 2006 190 198 (Pubitemid 44087117)
12. R. Rosell, T. Moran, and C. Queralt Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
13. C. Gridelli, F. Ciardiello, and C. Gallo et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial J Clin Oncol 30 2012 3002 3011
14. J.Y. Douillard, G. Ostoros, and M. Cobo et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study Br J Cancer 110 2014 55 62
15. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
16. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566 (Pubitemid 47206930)
17. S. Dearden, J. Stevens, Y.L. Wu, and D. Blowers Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Ann Oncol 24 2013 2371 2376
18. E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703 Erratum in: N Engl J Med 2011; 364:588
19. J.Y. Han, K. Park, and S.W. Kim et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
20. S. Oizumi, K. Kobayashi, and A. Inoue et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial Oncologist 17 2012 863 870
21. G. Chen, J. Feng, and C. Zhou et al. Quality of life analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer Ann Oncol 24 2013 1615 1622
22. J.C. Yang, V. Hirsh, and M. Schuler et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3342 3350
23. M. Di Maio, N.B. Leighl, and C. Gallo TORCH Investigators Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer J Thorac Oncol 7 2012 1830 1844
24. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh SATURN investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
25. L. Zhang, S. Ma, and X. Song INFORM investigators Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Lancet Oncol 13 2012 466 475
26. A.T. Shaw, B.Y. Yeap, and B.J. Solomon et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
27. A.T. Shaw, D.W. Kim, and K. Nakagawa et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
28. G. Ellison, G. Zhu, and A. Moulis et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples J Clin Pathol 66 2013 79 89
29. J.C.H. Yang, L.V. Sequist, and S.L. Geater et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer J Thorac Oncol 8 suppl 2 2013 S141
30. J.F. Gainor, A.M. Varghese, and S.H. Ou et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer Clin Cancer Res 19 2013 4273 4281
31. Y.L. Wu, and Q. Zhou Clinical trials and biomarker research on lung cancer in China Expert Opin Ther Targets 16 suppl 1 2012 S45 S50
32. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
33. A.J. Weickhardt, B. Scheier, and J.M. Burke et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
34. H.A. Yu, C.S. Sima, and J. Huang et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 8 2013 346 351
35. G.J. Riely, M.G. Kris, and B. Zhao et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clin Cancer Res 13 2007 5150 5155 (Pubitemid 47502083)
36. J.E. Chaft, G.R. Oxnard, and C.S. Sima et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design Clin Cancer Res 17 2011 6298 6303
37. A. Marchetti, A. Ardizzoni, and M. Papotti et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology J Thorac Oncol 8 2013 352 358
38. H. Nitta, K. Tsuta, and A. Yoshida et al. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, brightfield, dual ALK IHC-in situ hybridization assay J Thorac Oncol 8 2013 1019 1031
39. N. Peled, G. Palmer, and F.R. Hirsch et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer J Thorac Oncol 7 2012 e14 e16
40. J.M. Sun, Y.L. Choi, and J.K. Won et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC positive and FISH-negative ALK J Thorac Oncol 7 2012 e36 e38
41. D.R. Camidge, S.A. Kono, and X. Lu et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
42. J.O. Lee, T.M. Kim, and S.H. Lee et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
43. A.T. Shaw, A.M. Varghese, and B.J. Solomon et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer Ann Oncol 24 2013 59 66
44. D.R. Camidge, Y.J. Bang, and E.L. Kwak et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
45. C.A. Carter, and G. Giaccone Treatment of non small cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors Curr Opin Oncol 24 2012 123 129
46. R.C. Doebele, A.B. Pilling, and D.L. Aisner et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
47. S. Kim, T.M. Kim, and D.W. Kim et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer J Thorac Oncol 8 2013 415 422
48. S.V. Sharma, and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes Dev 21 2007 3214 3231 (Pubitemid 350277749)
49. U. Gatzemeier, A. Pluzanska, and A. Szczesna et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
50. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE Investigator Group TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
51. G. Giaccone, R. Herbst, and C. Manegold et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial- INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
52. R.S. Herbst, G. Giaccone, and J.H. Schiller et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
53. Y.L. Wu, J.S. Lee, and S. Thongprasert et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Lancet Oncol 14 2013 777 786
54. Y.Y. Janjigian, B.J. Park, and M.F. Zakowski et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations J Thorac Oncol 6 2011 569 575
55. J.W. Neal, N.A. Pennell, and R. Govindan et al. The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstract 7010